Exscientia and GSK announce strategic collaboration

08:13 EDT 5 Jul 2017 | EPM Magazine

Exscientia and GlaxoSmithKline (GSK) have entered into a strategic collaboration to apply an AI-enabled platform in the discovery of novel and selective small molecules for up to 10 disease-related targets.

Original Article: Exscientia and GSK announce strategic collaboration


More From BioPortfolio on "Exscientia and GSK announce strategic collaboration"

Quick Search


Relevant Topics

GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...